interleukin-6 and rheumatic diseases白细胞介素- 6和风湿性疾病.pdfVIP

Available online /content/8/S2/S4 Proceedings Interleukin-6 and rheumatic diseases Peter E Lipsky Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Rockville Pike, Bethesda, Maryland, USA Corresponding author: Peter E Lipsky, lipskyp@ Published: 28 July 2006 Arthritis Research Therapy 2006, 8(Suppl 2):S4 This article is online at /content/8/S2/S4 (doi:10.1186/ar1918) © 2006 BioMed Central Ltd Abstract synovial pannus formation and in bone resorption in inflamed IL-6 is a pleiotropic cytokine involved in both the initiation and the joints. IL-6 is also known to be an endogenous pyrogen [5] maintenance of the inflammatory and immunologic responses in and is the major cytokine inducer of acute phase response certain autoimmune diseases. Blocking of these two comple- genes [6]. Because of this panoply of activities, IL-6 is mentary functions of IL-6 may confer additive, or even unique, thought to play a critical role in synovial and systemic benefits to the patient. The levels of both IL-6 and its soluble inflammation in RA. receptor (sIL-6Rα) are elevated to various degrees in many rheumatic diseases. IL-6 blockade has been shown to be beneficial Animal models both in experimental models and in human disease, and inhibition of IL-6 signaling with a molecule such as tocilizumab could prevent Genetically manipulated mice have been useful in identifying or revers